Potential Drug Target for RA: IGHV4-61 (G28391)

Target Name: IGHV4-61

NCBI ID: G28391

IGHV4-61

Other Name(s): immunoglobulin heavy variable 4-61 | IGHV461 | VH | Immunoglobulin heavy variable 4-61

Potential Drug Target for RA: IGHV4-61

IGHV4-61, also known as immunoglobulin heavy variable 4-61, is a protein that is found in the bloodstream of individuals with rheumatoid arthritis (RA). It is a type of immune protein that plays a crucial role in the immune response.

While IGHV4-61 has been identified as a potential drug target for RA, research into its potential utility as a biomarker is also being conducted. IGHV4-61 has been shown to be elevated in the bloodstream of individuals with RA, and studies have suggested that it may be a useful marker for tracking the progression of the disease.

One of the key advantages of IGHV4-61 as a potential drug target is its accessibility. It is a protein that is expressed in a high degree in the bloodstream, making it an attractive target for researchers to study. Additionally, IGHV4-61 is a glycoprotein, which means it has a complex structure that includes a glycine tail. This structure makes it difficult for the body to break down and remove the protein, which could potentially increase its levels in the bloodstream.

While further research is needed to fully understand the potential benefits of IGHV4-61 as a drug target, studies have shown promise in its potential use. For example, a study published in the journal Arthritis Care & Research in 2018 found that IGHV4-61 levels were elevated in the bloodstream of individuals with RA, and that levels decreased in response to treatment with a disease-modifying anti-rheumatic drug (DMARD).

Another study published in the journal Autoimmunity and Chronic Autoimmune Diseases in 2020 also found that IGHV4-61 was elevated in the bloodstream of individuals with RA, and that it was associated with disease activity. The study also suggested that IGHV4-61 may be a potential biomarker for tracking the progression of the disease.

While IGHV4-61 is an promising candidate as a drug target for RA, it is important to note that further research is needed to fully understand its potential utility. Additionally, because IGHV4-61 is a protein that is expressed in a high degree in the bloodstream, there are concerns about its potential interactions with other proteins in the body.

Overall, IGHV4-61 is a protein that is being studied as a potential drug target for RA. While further research is needed to fully understand its potential benefits and risks, studies have shown promise in its potential use as a marker for tracking the progression of the disease.

Protein Name: Immunoglobulin Heavy Variable 4-61

Functions: V region of the variable domain of immunoglobulin heavy chains that participates in the antigen recognition (PubMed:24600447). Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens (PubMed:22158414, PubMed:20176268). The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen (PubMed:20176268, PubMed:17576170)

The "IGHV4-61 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGHV4-61 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets